#Denmark #Aarhus #Janine Schuurman #Commit Biologics #BiCE Platform

Commit Biologics Strengthens Leadership with New Board Appointment

Commit Biologics, known for its pioneering work in enhancing the complement system for the treatment of cancer and autoimmune diseases, has made a significant announcement regarding the expansion of its Board of Directors. Effective immediately, Dr. Janine Schuurman, a notable figure in antibody research with over 25 years of experience, joins the board in a move expected to accelerate the company's ongoing projects and drug development initiatives.

Dr. Janine Schuurman: A Proven Leader

Dr. Schuurman brings a wealth of experience from her previous role as Senior Vice President at Genmab, where she played a crucial part in developing multiple FDA-approved therapeutic antibodies. Among her significant contributions are the co-development of amivantamab (RYBREVANT®) and epcoritamab (EPKINLY®), demonstrating her extensive expertise in antibody technology. Her prior experience in managing scientific teams and collaborations with pharmaceutical companies positions her as an excellent fit for Commit Biologics as the company moves towards the nomination of drug candidates in the upcoming year.

Krishna Polu, MD, the Chief Executive Officer at Commit Biologics, expressed enthusiasm for the addition of Dr. Schuurman, noting, “Her extensive knowledge in antibody research and development will be instrumental for Commit as we advance our BiCE platform.” This leadership change aligns with Commit's objectives to enhance its therapeutic developments targeting cancer and autoimmune diseases carefully.

The BiCE Platform: Shaping Future Therapies

Commit Biologics has been advancing its Bispecific Complement Engaging (BiCE™) technology, which is designed to effectively harness the body's immune system to combat disease. This innovative platform combines single-domain antibodies with conventional antibodies to activate the complement system — a critical part of the immune defense mechanism that has historically been underutilized in therapeutic applications.

The potential of the BiCE platform lies in its ability to precisely target tumor cells and autoimmune disease cells by redirecting the complement system in a selective manner. This offers an entirely new therapeutic approach, enabling the development of treatments that can either stand alone or be used in combination therapies. Dr. Schuurman's involvement is anticipated to catalyze the transition of BiCE from pipeline concepts to viable drug candidates, with projections set for 2025.

Commit Biologics and the Future of Immunotherapy

The incorporation of Dr. Schuurman into the board is a strategic move reflecting Commit Biologics' commitment to innovation in immunotherapy. With the firm backed by major investors such as Bioqube Ventures and Novo Holdings, it is poised for substantial advancements and impactful breakthroughs in immune-based therapies.

As Dr. Schuurman takes up her role, she expressed her excitement about the prospects of the BiCE technology, stating, “The technology behind BiCE is particularly exciting because of its potential to significantly activate the complement system against targeted diseases.” Her insights are expected to reshape the therapeutic landscape for patients suffering from complex and challenging conditions.

Conclusion

In summary, Dr. Janine Schuurman's appointment to the Board of Commit Biologics is expected to bring transformative changes to the company’s strategic focus on antibody-based therapies and the advancement of its BiCE platform. As the company prepares to move forward with its clinical developments, the combination of seasoned leadership and innovative technology stands to offer hope and improved treatment options for patients with cancer and autoimmune diseases.